Welcome to our dedicated page for Citius Oncology news (Ticker: CTOR), a resource for investors and traders seeking the latest updates and insights on Citius Oncology stock.
Citius Oncology, Inc. reports developments tied to its oncology-focused biopharmaceutical business and the commercialization of LYMPHIR™ (denileukin diftitox-cxdl). The company is a majority-owned subsidiary of Citius Pharmaceuticals and develops targeted oncology therapies. LYMPHIR is FDA approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma who have received at least one prior systemic therapy.
Recurring CTOR news includes U.S. launch updates, initial revenue and operating results, institutional adoption, payer coverage, international distribution through regional partners and Named Patient Programs, and investigator-led clinical studies involving LYMPHIR in additional oncology settings. Company updates also cover medical-affairs engagement, material agreements, shareholder voting matters, capital-structure disclosures, governance matters, and clinical or regulatory disclosures.
Citius Oncology (Nasdaq: CTOR) announced on October 7, 2025 that it is expanding international access to LYMPHIR™ (denileukin diftitox-cxdl) via country-specific Named Patient Programs (NPPs) in Europe, South America and the Middle East.
The company signed an exclusive distribution agreement with Integris Pharma S.A., headquartered in Athens, to cover Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia. NPPs provide early patient access prior to full marketing authorization and do not constitute commercial approval outside the U.S.
Citius Oncology (NASDAQ: CTOR) has successfully closed its previously announced financing round, consisting of a registered direct offering and concurrent private placement. The company raised $9.0 million in gross proceeds through the sale of 5,142,858 shares of common stock and warrants at a combined price of $1.75 per share.
The offering included unregistered warrants to purchase up to 5,142,858 additional shares at an exercise price of $1.84 per share. These warrants will become exercisable after six months and expire five and a half years from issuance. Maxim Group LLC served as the sole placement agent for the transaction.
Citius Oncology (NASDAQ:CTOR) has announced a $9.0 million registered direct offering and concurrent private placement. The company will issue 5,142,858 shares of common stock at a combined effective price of $1.75 per share to a single institutional investor.
The deal includes unregistered warrants to purchase an additional 5,142,858 shares at an exercise price of $1.84 per share. These warrants will be exercisable after six months and expire 5.5 years from issuance. The offering is expected to close around September 10, 2025, with Maxim Group LLC serving as the sole placement agent.
Citius Oncology (NASDAQ:CTOR) has announced the deployment of a proprietary AI platform to enhance its commercial team's performance ahead of the anticipated LYMPHIR™ launch for cutaneous T-cell lymphoma (CTCL) treatment. The platform leverages advanced data analytics and machine learning to identify potential LYMPHIR candidates and optimize healthcare provider engagement.
The AI system analyzes treatment patterns and diagnosis data to support targeted prescriber outreach. It features a continuous learning model that integrates real-world U.S. claims data and marketing performance analytics to deliver predictive insights and enable personalized customer engagement across digital and in-person channels.
Citius Oncology (NASDAQ:CTOR) reported its fiscal Q3 2025 results and provided updates on its commercial launch preparations for LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma. The company secured $12.5 million in financing during Q3, with an additional $9 million raised in July 2025, to support LYMPHIR's market introduction planned for Q4 2025.
Financial results showed a net loss of $5.4 million ($0.08 per share), compared to $4.8 million ($0.07 per share) in Q3 2024. R&D expenses decreased to $938,000 from $1.1 million year-over-year, while G&A expenses increased to $1.9 million from $1.5 million. The company reported $112 in cash with 71,552,402 common shares outstanding as of June 30, 2025.
Citius Oncology (NASDAQ:CTOR) has successfully closed its public offering, raising approximately $9.0 million in gross proceeds. The offering consisted of 6,818,182 shares of common stock and warrants at a public offering price of $1.32 per share.
The warrants are immediately exercisable at $1.32 per share and will expire in five years. The company plans to use the proceeds primarily to support the commercialization of LYMPHIR, including milestone and royalty payments, as well as for working capital and general corporate purposes. Maxim Group LLC served as the sole placement agent for this "reasonable best-efforts" offering.
Citius Oncology (NASDAQ:CTOR) has announced the pricing of a public offering to raise $9.0 million through the sale of 6,818,182 shares of common stock and warrants at $1.32 per share. The warrants will have the same exercise price, be immediately exercisable, and expire in five years.
The company plans to use the proceeds primarily for the commercialization of LYMPHIR, including milestone and royalty payments, as well as working capital. The offering, managed by Maxim Group LLC as sole placement agent, is expected to close around July 17, 2025.
Citius Oncology (NASDAQ:CTOR) has signed a distribution services agreement with Cencora (formerly AmerisourceBergen) for its FDA-approved immunotherapy LYMPHIR™. The agreement enhances the company's commercial infrastructure for the distribution of LYMPHIR, which treats relapsed or refractory cutaneous T-cell lymphoma (CTCL).
This partnership expands Citius Oncology's distribution network and complements a previously announced distribution agreement, strengthening the company's market reach and supporting long-term scalability. Under the agreement, Cencora will serve as a wholesale distributor for LYMPHIR, facilitating product availability across its distribution network.